Autocrine insulin-like growth factor-I signaling promotes growth and survival of human acute myeloid leukemia cells via the phosphoinositide 3-kinase/Akt pathway

被引:102
作者
Doepfner, K. T.
Spertini, O.
Arcaro, A.
机构
[1] Univ Childrens Hosp Zurich, Div Clin Chem & Biochem, CH-8032 Zurich, Switzerland
[2] Univ Vaudois, Ctr Hosp, Serv & Cent Lab Hematol, Lausanne, Switzerland
关键词
acute myeloid leukemia; insulin-like growth factor; phosphoinositide; 3-kinase; Akt; apoptosis;
D O I
10.1038/sj.leu.2404813
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Insulin- like growth factor ( IGF) signaling plays an important role in various human cancers. Therefore, the role of insulinlike growth factor I ( IGF- I) signaling in growth and survival of acute myeloid leukemia ( AML) cells was investigated. Expression of the IGF- I receptor ( IGF- IR) and its ligand IGF- I were detected in a panel of human AML blasts and cell lines. IGF- I and insulin promoted the growth of human AML blasts in vitro and activated the phosphoinositide 3- kinase ( PI3K)/ Akt and the extracellular signal- regulated kinase ( Erk) pathways. IGF- Istimulated growth of AML blasts was blocked by an inhibitor of the PI3K/ Akt pathway. Moreover, downregulation of the class Ia PI3K isoforms p110 beta and p110 delta by RNA interference impaired IGF- I- stimulated Akt activation, cell growth and survival in AML cells. Proliferation of a panel of AML cell lines and blasts isolated from patients with AML was inhibited by the IGF- IR kinase inhibitor NVP- AEW541 or by an IGF- IR neutralizing antibody. In addition to its antiproliferative effects, NVPAEW541 sensitized primary AML blasts and cell lines to etoposide- induced apoptosis. Together, our data describe a novel role for autocrine IGF- I signaling in the growth and survival of primary AML cells. IGF- IR inhibitors in combination with chemotherapeutic agents may represent a novel approach to target human AML.
引用
收藏
页码:1921 / 1930
页数:10
相关论文
共 52 条
[1]   Mutational analysis of the tumour suppressor gene MMAC1/PTEN in malignant myeloid disorders [J].
Aggerholm, A ;
Gronbæk, K ;
Guldberg, P ;
Hokland, P .
EUROPEAN JOURNAL OF HAEMATOLOGY, 2000, 65 (02) :109-113
[2]   Cellular vascular endothelial growth factor is a predictor of outcome in patients with acute myeloid leukemia [J].
Aguayo, A ;
Estey, E ;
Kantarjian, H ;
Mansouri, T ;
Gidel, C ;
Keating, M ;
Giles, F ;
Estrov, Z ;
Barlogie, B ;
Albitar, M .
BLOOD, 1999, 94 (11) :3717-3721
[3]   A large-scale RNAi screen in human cells identifies new components of the p53 pathway [J].
Berns, K ;
Hijmans, EM ;
Mullenders, J ;
Brummelkamp, TR ;
Velds, A ;
Heimerikx, M ;
Kerkhoven, RM ;
Madiredjo, M ;
Nijkamp, W ;
Weigelt, B ;
Agami, R ;
Ge, W ;
Cavet, G ;
Linsley, PS ;
Beijersbergen, RL ;
Bernards, R .
NATURE, 2004, 428 (6981) :431-437
[4]   Synergy between an IGF-1R antibody and Raf/MEK/ERK and PI3K/Akt/mTOR pathway inhibitors in suppressing IGF-1R-mediated growth in hematopoietic cells [J].
Bertrand, F. E. ;
Steelman, L. S. ;
Chappell, W. H. ;
Abrams, S. L. ;
Shelton, J. G. ;
White, E. R. ;
Ludwig, D. L. ;
McCubrey, J. A. .
LEUKEMIA, 2006, 20 (07) :1254-1260
[5]  
Bieker R, 2003, CANCER RES, V63, P7241
[6]   A selective inhibitor of the p110δ isoform of PI 3-kinase inhibits AML cell proliferation and survival and increases the cytotoxic effects of VP16 [J].
Billottet, C. ;
Grandage, V. L. ;
Gale, R. E. ;
Quattropani, A. ;
Rommel, C. ;
Vanhaesebroeck, B. ;
Khwaja, A. .
ONCOGENE, 2006, 25 (50) :6648-6659
[7]   FLT3 Inhibitors: a paradigm for the development of targeted therapeutics for paediatric cancer [J].
Brown, P ;
Small, D .
EUROPEAN JOURNAL OF CANCER, 2004, 40 (05) :707-721
[8]  
Ciardiello F, 2000, CLIN CANCER RES, V6, P2053
[9]   Changes of serum growth factors (IGF-I,-II and IGFBP-2,-3) prior to and after stem cell transplantation in children with acute leukemia [J].
Dawczynski, K ;
Kauf, E ;
Zintl, F .
BONE MARROW TRANSPLANTATION, 2003, 32 (04) :411-415
[10]   Vascular endothelial growth factor, a possible paracrine growth factor in human acute myeloid leukemia [J].
Fiedler, W ;
Graeven, U ;
Ergun, S ;
Verago, S ;
Kilic, N ;
Stockschlader, M ;
Hossfeld, DK .
BLOOD, 1997, 89 (06) :1870-1875